Telix Pharmaceuticals | TLX - 销售和管理费用



金融业
股票价格
AUD
资产
AUD 1.36B
现金及等价物
AUD 141.87M
销售成本
AUD 245.71M
流动资产
AUD 488.02M
流动负债
AUD 242.34M
债务
AUD 467.11M
EBIT
AUD 46.36M
EBITDA
AUD 76.49M
EPS每股收益
AUD 0.1
股本和储备
AUD 408.17M
销售毛利
AUD 260.35M
债务利息支出
AUD 19.39M
利息收入
AUD 1.37M
贷款资金
AUD 564.44M
市值
AUD 5.34B
净收入
AUD 38.33M
营业费用
AUD 430.99M
营业利润
AUD 46.36M
普通股股本
AUD 339.79M
PE价格收益
223.36
税前利润
AUD 76.73M
销售收入
AUD 477.35M
销售和管理费用
AUD 107.02M
股票
AUD 37.08M
贸易债权人
AUD 168.97M
应收帐款人
AUD 170.39M


销售和管理费用 更改 日
Cochlear AUD 449.4M 214.45M 2025-12
CSL USD 1.23B 498M 2025-12
Integral Diagnostics AUD 169.98M 18.73M 2024-06
Mayne Pharma AUD 54.8M 11.94M 2024-06
Medical Developments International AUD 2.84M 4.19M 2025-12
Mesoblast USD 85.89M 57.35M 2026-06
Neuren Pharmaceuticals AUD 3.74M 2.5M 2025-12
Pacific Edge NZD 16.75M 2.42M 2026-06
Paradigm Biopharmaceuticals AUD 2.83M 1.22M 2025-12
Polynovo AUD 17.04M 1.91M 2025-12
PYC Therapeutics AUD 328.4K 1.8M 2025-12
Ramsay Health Care AUD 5.29B 3.2M 2024-12
ResMed USD 285.65M 9.96M 2026-03
Sonic Healthcare AUD 2.52B 2.46B 2024-12